Core Viewpoint - The Law Offices of Frank R. Cruz is reminding investors about the September 22, 2025 deadline to participate as a lead plaintiff in a securities fraud class action lawsuit against RxSight, Inc. for investors who acquired its securities during the specified class period [1] Group 1 - The class action lawsuit is on behalf of investors who purchased RxSight, Inc. securities between May 7, 2024, and July 8, 2025 [1] - Investors who lost money on RxSight, Inc. are encouraged to participate in the securities fraud lawsuit [1]

Group 1 - A class action securities lawsuit has been filed against RxSight, Inc. [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical issues affecting the company's performance [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from November 7, 2024, to July 8, 2025 [3]. - Allegations include: - The company faced "adoption challenges" and structural issues leading to declines in sales and utilization [3]. - Defendants allegedly overstated the demand for RxSight's products [3]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 [3]. - Positive statements made by defendants regarding the company's business and prospects were materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to participate in potential recovery [4]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Group 1 - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding potential legal matters [1]

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's growth and performance during the specified Class Period [1][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company specializing in cataract treatment, with its main product being the RxSight Light Adjustable Lens system, which includes an intraocular light adjustable lens and a light delivery device [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight and its executives misrepresented the company's growth, stating that utilization was rising and that newer customer cohorts were adopting the technology at a comparable or faster rate than previous cohorts. In reality, the company faced challenges with its field organization, leading to slower adoption and declining utilization [4]. - The lawsuit highlights that incremental placements of light delivery devices did not result in the expected volume of lens procedures, undermining the company's growth model [4]. Impact of Disclosures - On April 2, 2025, RxSight reported a sequential decline in quarterly lens sales and reduced its full-year revenue guidance by approximately $24 million, resulting in a 38% drop in the stock price [5]. - Further disclosures on July 8, 2025, revealed a 45% sequential decline in light delivery device sales and a second consecutive quarter of declining lens sales, leading to another 38% decrease in stock price [6]. Legal Representation - The plaintiffs in the lawsuit are represented by Robbins Geller Rudman & Dowd LLP, a law firm with significant experience in prosecuting investor class actions related to financial fraud [7].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false or misleading statements regarding its financial performance and product demand during the specified class period [7]. Allegation Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization of its products [7]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [7]. Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [7]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell nearly 38% [7]. Next Steps - Investors who purchased RxSight shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc., following a class action lawsuit filed on behalf of investors who acquired RxSight securities between May 7, 2024, and July 8, 2025 [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery, utilizing the Company's Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the stall in LDD sales to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, and investors who purchased securities between May 7, 2024, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees [1][2] - Investors wishing to serve as lead plaintiff must file a motion with the Court by September 22, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that RxSight misrepresented the performance of its field organization and the adoption rates of newer customer cohorts, leading to inflated stock prices [4] - It is claimed that the actual utilization across the installed base was declining, contradicting the company's statements about growth and support [4]

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning RxSight business and prospects, resulting in its stock trading at inflated prices. ...